PD-1 antibodies inhibit the interaction between PD-1 and PD-L1/PD-L2, resulting in greater T-cell numbers, increased cytotoxicity, upregulation of cytokine production, and, ultimately, tumor cell lysis (Wang et al., 2018) (Figure 1B). The gene discussed is PDCD1LG2; the disease is neoplasm.